SCHEMBL6574956

SCHEMBL6574956

CC(C)n1cnc2c(Nc3cccc(C(N)=O)c3)nc(NC3CCC(O)CC3)nc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 8/20 0.65
FLT3 P36888 2/20 0.57
CDK2 P24941 6/20 0.56
CCNE1 P24864 5/20 0.56
CCNE2 O96020 2/20 0.56
CCNA2 P20248 2/20 0.56
CCNA1 P78396 2/20 0.56
CLK1 P49759 6/20 0.55
CLK2 P49760 6/20 0.55
CLK4 Q9HAZ1 6/20 0.55
CCNB1 P14635 2/20 0.55
CDK4 P11802 1/20 0.55
CCND3 P30281 1/20 0.55
CDK5 Q00535 2/20 0.53
CDK5R1 Q15078 2/20 0.53
CCNT1 O60563 1/20 0.53
CDK7 P50613 1/20 0.53
CDK9 P50750 1/20 0.53
CCNH P51946 1/20 0.53
PDGFRA P16234 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6574922 0.89 CDK1 (0.71) CDK1FLT3CDK2CCNE1CCNE2
SCHEMBL6578423 0.86 CDK1 (0.75) CDK1CDK2CCNE1CCNA2CLK1
SCHEMBL6576348 0.86 CDK1 (0.75) CDK1CDK2CCNE1CCNA2CLK1
SCHEMBL6775420 0.83 CCNE2 (0.63) CDK1CDK2CCNE1CCNE2CCNA2
SCHEMBL6770758 0.81 CDK1 (0.56) CDK1FLT3CDK2CCNE1CCNE2
SCHEMBL6574897 0.81 CDK1 (0.59) CDK1FLT3CDK2CCNE1CCNE2
SCHEMBL25737311 0.80 CDK1 (0.71) CDK1FLT3CDK2CCNE1CLK1
SCHEMBL6576946 0.80 CCNE2 (0.60) CDK1CDK2CCNE1CCNE2CCNA2
SCHEMBL6770594 0.80 CDK1 (0.55) CDK1FLT3CDK2CCNE1CCNE2
SCHEMBL25736248 0.80 CDK1 (0.61) CDK1FLT3CDK2CCNE1CCNE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1153024-B1 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2004-04-28 EP claimed
JP-2002537300-A 2002-11-05 JP claimed
US-20020016329-A1 2-Amino-6-anilino-purines and their use as medicaments NOVARTIS AG (CH) 2002-02-07 US claimed
EP-1153024-A1 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS Novartis AG (CH) 2001-11-14 EP claimed
WO-2000049018-A1 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2000-08-24 WO claimed
EP-1153024-B1 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2004-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016329-A1 2-Amino-6-anilino-purines and their use as medicaments CDK14, CDK1, CCNB1 CDK1 2/4885FLT3 357/4885CDK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.